Jatin Shah M.D.
As Karyopharm’s Senior Vice President, Clinical Development, Dr. Jatin Shah is responsible for overseeing the company’s ongoing clinical programs.
Dr. Shah brings significant medical oncology experience to Karyopharm from his prior work at The University of Texas MD Anderson Cancer Center (MD Anderson), including work as a treating physician for patients with multiple myeloma and clinical research. For nearly ten years at MD Anderson, Dr. Shah served as an Associate Professor and Associate Program Director of the Malignant Hematology Fellowship, as well as Director of Myeloma Clinical and Translational Research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine.
Dr. Shah received his medical degree from Ohio State University College of Medicine, Columbus, Ohio, and his undergraduate degree, also from Ohio State University, in Mechanical Engineering. He completed an internship and residency in internal medicine at the Cleveland Clinic Foundation, Cleveland, Ohio, and a fellowship in hematology/oncology at the University of Alabama at Birmingham. Dr. Shah holds board certification in hematology and oncology from the American Board of Internal Medicine. He has served as principal investigator/co-investigator for numerous relapsed/refractory multiple myeloma studies and has published articles and abstracts in many peer-reviewed journals.